CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 28 enrolled
Drug / intervention
miRNAother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07315737
NCT07315737N/ACompleted

miRNAs Associated With Undescended and Retractile Testes

Dr. Mevlüt Keleş·observational·Posted Jan 2, 2026·Updated Jan 2, 2026

In Brief

An observational study evaluating miRNA for MIRAS and 2 related conditions. Completed, enrolled 28 participants across 1 site.

Detailed Summary

Background: Undescended testicles (UDTs) are common in male infants. Untreated UDT poses risks such as infertility (IF), testicular cancer (TC), and testicular torsion (TT). Retractile testicles (RTs) sporadically ascend from the scrotum. UDT requires early surgical correction, whereas RT requires only periodic follow-up. Differentiating these conditions is challenging, making clinical biomarkers potentially useful. The aim of our study was to examine the use of miRNAs, which are difficult to differentiate, as biomarkers in the differential diagnosis of UDT and RT. Methods: This prospective study included 10 boys with UDT (operated), 9 with RT (followed), and 9 controls. Parent consent and serum samples were collected to evaluate miR-210, miR-34c, and miR-449a expression via real-time PCR. For group comparisons, one-way ANOVA was used for parametric data, and the Kruskal-Wallis test was used for nonparametric data, followed by the Dunn-Bonferroni correction for post hoc multiple comparisons. Spearman's rank correlation coefficient was used to analyse correlations. A p value \< 0.05 was considered significant.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedJan 2, 2026
Enrollment StartMar 1, 2022
Primary CompletionMar 31, 2023
Study CompletionApr 30, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 6 months ago

Interventions

miRNAother

miR-34c , miR-210 , miR-449a levels investigated.